Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

erlotinib

Known as: N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine, [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine 
A quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Activating mutations of the epidermal growth factor receptor gene (EGFR) are a driving force for some lung adenocarcinomas… Expand
  • table 1
  • figure 1
Is this relevant?
Review
2017
Review
2017
Pancreatic ductal adenocarcinoma (PDAC), commonly referred to as pancreatic cancer, ranks among the leading causes of cancer… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2007
Highly Cited
2007
PURPOSE Patients with advanced pancreatic cancer have a poor prognosis and there have been no improvements in survival since the… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
In human lung adenocarcinomas harboring EGFR mutations, a second-site point mutation that substitutes methionine for threonine at… Expand
  • figure 1
  • table 1
  • table 2
  • figure 3
  • figure 2
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND We conducted a randomized, placebo-controlled, double-blind trial to determine whether the epidermal growth factor… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Background Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND A clinical trial that compared erlotinib with a placebo for non-small-cell lung cancer demonstrated a survival benefit… Expand
  • table 1
  • figure 2
  • table 2
  • figure 3
  • table 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Background Somatic mutations in the gene for the epidermal growth factor receptor (EGFR) are found in adenocarcinomas of the lung… Expand
  • table 1
  • figure 1
  • table 2
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?